Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

SMC Update - January 2014

The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.

Fentanyl citrate (Breakyl®) has been rejected for the treatment of breakthrough pain (BTP) in adults with cancer who are already receiving maintenance opioid therapy for chronic cancer pain. The manufacturer failed to make a submission.

Saxagliptin / Metformin (Kombogylze®) has been accepted for use in the treatment of type 2 diabetes mellitus in adults as triple oral therapy (in combination with a sulphonylurea) to improve glycaemic control when dual therapy (with metformin and a sulphonylurea), in combination with diet and exercise, does not provide adequate glycaemic control.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.

Share 'SMC Update - January 2014' on Email Share 'SMC Update - January 2014' on Delicious Share 'SMC Update - January 2014' on Digg Share 'SMC Update - January 2014' on Facebook Share 'SMC Update - January 2014' on Google+ Share 'SMC Update - January 2014' on reddit Share 'SMC Update - January 2014' on StumbleUpon Share 'SMC Update - January 2014' on Twitter

atomic-wealth

No Comments to “SMC Update - January 2014”

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.

atomic-wealth
fond-illness
summer